Eli Lilly Boosts 2025 Outlook Amid Strong Weight-Loss Drug Sales

Eli Lilly raised its 2025 sales and earnings guidance driven by strong demand for its weight loss and diabetes drugs Mounjaro and Zepbound, with second-quarter earnings surpassing estimates. The company also released trial data for its obesity pill, forglipron, which showed promising weight loss results but fell short of expectations, causing shares to drop. Despite robust revenue growth, Eli Lilly faces potential U.S. import tariffs and political pressure to lower drug prices.